The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
Your search for supplemental oxygen returned 4 results
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.
The update was based on data from the COV-BARRIER study.
Findings showed that the trial did not meet statistical significance on the primary endpoint.
- Loading...
